

Bruno H R De Paula

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/682762/publications.pdf>

Version: 2024-02-01

78
papers

4,773
citations

331670

21
h-index

110387

64
g-index

80
all docs

80
docs citations

80
times ranked

5781
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting HER2 for localised oesophageal cancer. <i>Lancet Oncology</i> , The, 2022, 23, 188-190.	10.7	0
2	Low Programmed Death-Ligand 1â€“Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 392-402.	1.6	87
3	Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe. <i>European Journal of Cancer</i> , 2022, 164, 18-29.	2.8	27
4	Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy. <i>BioDrugs</i> , 2022, 36, 473-485.	4.6	5
5	EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers. <i>Gut</i> , 2021, 70, 1632-1641.	12.1	24
6	Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 535-546.	2.4	9
7	Anti-cancer therapy with cyclin-dependent kinase inhibitors: impact and challenges. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e6.	3.9	10
8	Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins. <i>Acta OncolÃ³gica</i> , 2021, 60, 672-680.	1.8	3
9	Personalising care in oesophageal cancer care with liquid biopsy. <i>British Journal of Cancer</i> , 2021, 125, 1036-1038.	6.4	1
10	Results from a global survey of clinical cancer researchers on clinical trial design and conduct during the COVID-19 pandemic and beyond.. <i>Journal of Clinical Oncology</i> , 2021, 39, e13576-e13576.	1.6	0
11	Serial Circulating Tumor DNA Detection Using a Personalized, Tumor-Informed Assay in Esophageal Adenocarcinoma Patients Following Resection. <i>Gastroenterology</i> , 2021, 161, 1705-1708.e2.	1.3	8
12	The role of surgery after prolonged primary chemotherapy for advanced oesophageal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2021, 124, 1296-1305.	1.7	0
13	Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. <i>British Journal of Cancer</i> , 2021, 125, 911-919.	6.4	3
14	Cannabinoids in glioblastoma multiformeâ€”hype or hope?. <i>British Journal of Cancer</i> , 2021, 124, 1341-1343.	6.4	14
15	Response of NOTCH1-Activated Tracheal Adenoid Cystic Carcinoma to the Gamma Secretase Inhibitor Nirogacestat. <i>JCO Precision Oncology</i> , 2021, 5, 1579-1583.	3.0	1
16	Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes. <i>Cancer Treatment Reviews</i> , 2020, 84, 101950.	7.7	19
17	Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer. <i>European Journal of Cancer</i> , 2020, 124, 67-76.	2.8	16
18	Sociodemographic, Clinical, and Pathological Factors Influencing Outcomes in Locally Advanced Triple Negative Breast Cancer: A Brazilian Cohort. <i>Breast Cancer: Basic and Clinical Research</i> , 2020, 14, 117822342096248.	1.1	3

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab in First-line Gastric Cancer. <i>JAMA Oncology</i> , 2020, 6, 1539.	7.1	8
20	Gastric cancer. <i>Lancet</i> , The, 2020, 396, 635-648.	13.7	2,084
21	Addition of nivolumab to chemotherapy in patients with advanced gastric cancer: a relevant step ahead, but still many questions to answer. <i>ESMO Open</i> , 2020, 5, e001107.	4.5	8
22	Young patients with cancer and a digital social network: the voice beyond the clinic. <i>ESMO Open</i> , 2020, 5, e000651.	4.5	9
23	Rethinking cancer clinical trials for COVID-19 and beyond. <i>Nature Cancer</i> , 2020, 1, 568-572.	13.2	38
24	A global perspective on oesophageal cancer: two diseases in one. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 521-522.	8.1	9
25	Predictive Biomarkers of Immune Checkpoint Inhibition in Gastroesophageal Cancers. <i>Frontiers in Oncology</i> , 2020, 10, 763.	2.8	32
26	Recommendations from national regulatory agencies for ongoing cancer trials during the COVID-19 pandemic. <i>Lancet Oncology</i> , The, 2020, 21, 624-627.	10.7	27
27	Adjuvant chemotherapy for malignant phyllodes tumor of the breast. <i>World Journal of Advanced Research and Reviews</i> , 2020, 5, 048-054.	0.2	2
28	Colorectal liver metastases: Current management and future perspectives. <i>World Journal of Clinical Oncology</i> , 2020, 11, 761-808.	2.3	98
29	Safety and preliminary signs of efficacy with the combination of pembrolizumab plus oxaliplatin and S-1 in Japanese gastric cancer patients. <i>Annals of Translational Medicine</i> , 2020, 8, 1696-1696.	1.7	0
30	Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patients's™ Prognosis. <i>International Journal of Surgical Pathology</i> , 2019, 27, 816-835.	0.8	8
31	Late-line treatment in metastatic gastric cancer: today and tomorrow. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591986752.	3.2	37
32	Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma. <i>JAMA Oncology</i> , 2019, 5, 1181.	7.1	12
33	Social networks for young patients with cancer: the time for system agility. <i>Lancet Oncology</i> , The, 2019, 20, 765.	10.7	11
34	Neoadjuvant zoledronic acid for HER2-positive breast cancer: the Zo-NAnTax trial. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985397.	3.2	6
35	Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer. <i>ESMO Open</i> , 2019, 4, e000591.	4.5	0
36	Two steps forward and one step back. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 69-70.	27.6	6

#	ARTICLE	IF	CITATIONS
37	Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer. <i>Drugs</i> , 2019, 79, 1-10.	10.9	18
38	Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy – results from the <scp>MRC OE</scp>02 oesophageal cancer trial. <i>Histopathology</i> , 2018, 72, 1180-1188.	2.9	31
39	The Role of Microsatellite Instability in Positive Margin Gastric Cancer Patients. <i>Surgical Innovation</i> , 2018, 25, 99-104.	0.9	14
40	Synchronous metastatic gastric cancer-molecular background and clinical implications with special attention to mismatch repair deficiency. <i>European Journal of Surgical Oncology</i> , 2018, 44, 626-631.	1.0	16
41	Adjuvant Chemotherapy Following Neoadjuvant Chemotherapy Plus Surgery for Patients With Gastroesophageal Cancer – Is There Room for Improvement?. <i>JAMA Oncology</i> , 2018, 4, 38.	7.1	3
42	Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 36-37, 45-52.	2.4	13
43	MUC16 Mutations and Prognosis in Gastric Cancer. <i>JAMA Oncology</i> , 2018, 4, 1698.	7.1	4
44	Pembrolizumab versus paclitaxel in gastro-oesophageal adenocarcinoma. <i>Lancet, The</i> , 2018, 392, 97-98.	13.7	5
45	Genomic loss of heterozygosity and survival in the REAL3 trial. <i>Oncotarget</i> , 2018, 9, 36654-36665.	1.8	13
46	Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer. <i>Chinese Clinical Oncology</i> , 2018, 7, 25-25.	1.2	24
47	Mismatch Repair Deficiency, Microsatellite Instability, and Survival. <i>JAMA Oncology</i> , 2017, 3, 1197.	7.1	398
48	Gatekeeper Mutations and Intratumoral Heterogeneity in <i>FGFR2</i>-Translocated Cholangiocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 248-249.	9.4	13
49	Staging in Esophageal and Gastric Cancers. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 427-440.	2.2	30
50	Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. <i>Clinical Cancer Research</i> , 2017, 23, 7543-7549.	7.0	12
51	Oesophageal cancer. <i>Nature Reviews Disease Primers</i> , 2017, 3, 17048.	30.5	671
52	Missing a GOLDen opportunity in gastric cancer. <i>Lancet Oncology, The</i> , 2017, 18, 1561-1563.	10.7	11
53	First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. <i>Oncotarget</i> , 2017, 8, 111795-111806.	1.8	6
54	Regorafenib in gastric cancer. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 16-16.	3.0	2

#	ARTICLE	IF	CITATIONS
55	Neoadjuvant DCF vs. ACF for resectable oesophageal squamous cell carcinoma. <i>Journal of Thoracic Disease</i> , 2017, 9, 2868-2870.	1.4	0
56	Emerging molecular targets and therapy for cholangiocarcinoma. <i>World Journal of Gastrointestinal Oncology</i> , 2017, 9, 268.	2.0	27
57	High-Level Clonal <i>FGFR</i> Amplification and Response to <i>FGFR</i> Inhibition in a Translational Clinical Trial. <i>Cancer Discovery</i> , 2016, 6, 838-851.	9.4	222
58	Novel targets in the treatment of advanced gastric cancer: a perspective review. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 113-125.	3.2	54
59	Encouraging results for PD-1 inhibition in gastric cancer. <i>Lancet Oncology</i> , The, 2016, 17, 682-683.	10.7	14
60	Efficacy and toxicity of salvage weekly paclitaxel chemotherapy in non-Asian patients with advanced oesophagogastric adenocarcinoma. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 104-112.	3.2	6
61	Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 2721-2727.	1.6	214
62	Exclusion of Gastrointestinal Cancer Patients With Prior Cancer From Clinical Trials: Is This Justified?. <i>Clinical Colorectal Cancer</i> , 2016, 15, e53-e59.	2.3	27
63	<i>AREG</i> and <i>EREG</i> as Predictive Biomarkers for <i>RAS</i> Wild-Type Colorectal Cancer Treated With Panitumumab. <i>JAMA Oncology</i> , 2016, 2, 578.	7.1	8
64	Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001-2010. <i>Gastric Cancer</i> , 2016, 19, 1114-1124.	5.3	8
65	Technical Reproducibility of Single-Nucleotide and Size-Based DNA Biomarker Assessment Using DNA Extracted from Formalin-Fixed, Paraffin-Embedded Tissues. <i>Journal of Molecular Diagnostics</i> , 2015, 17, 242-250.	2.8	8
66	The Preoperative Lymphocyte-to-Monocyte Ratio is Prognostic of Clinical Outcomes for Patients with Liver-Only Colorectal Metastases in the Neoadjuvant Setting. <i>Annals of Surgical Oncology</i> , 2015, 22, 4353-4362.	1.5	47
67	Reply to R.C. Turkington et al. <i>Journal of Clinical Oncology</i> , 2015, 33, 1089-1090.	1.6	0
68	Personalizing the management of gastroesophageal cancer. <i>Personalized Medicine</i> , 2015, 12, 447-451.	1.5	0
69	Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma. <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 373-383.	3.2	22
70	Epirubicin, Cisplatin, and Capecitabine Versus Fluorouracil, Leucovorin, and Irinotecan for Esophagogastric Cancer: The Original and the Rest. <i>Journal of Clinical Oncology</i> , 2015, 33, 2409-2409.	1.6	7
71	Ramucirumab: targeting angiogenesis in the treatment of gastric cancer. <i>Immunotherapy</i> , 2014, 6, 1177-1186.	2.0	6
72	Optimal Management of Esophageal Adenocarcinoma: Should We Be CROSS?. <i>Journal of Clinical Oncology</i> , 2014, 32, 3080-3081.	1.6	6

#	ARTICLE	IF	CITATIONS
73	Ramucirumab: Successfully Targeting Angiogenesis in Gastric Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5875-5881.	7.0	82
74	Operable gastro-oesophageal junctional adenocarcinoma: Where to next?. <i>World Journal of Gastrointestinal Oncology</i> , 2014, 6, 145.	2.0	2
75	Defining treatment standards and novel insights into disease biology. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 73-74.	27.6	33
76	Gastrointestinal oncology “ what you need to know. <i>Clinical Medicine</i> , 2012, 12, 575-579.	1.9	0
77	Targeted Therapy for Gastric Cancer. <i>Current Treatment Options in Oncology</i> , 2012, 13, 377-389.	3.0	62
78	ST03: A randomized trial of perioperative epirubicin, cisplatin plus capecitabine (ECX) with or without bevacizumab (B) in patients (pts) with operable gastric, oesophagogastric junction (OGJ) or lower oesophageal adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS4143-TPS4143.	1.6	9